Why a complete medicine list matters in peptide care

Write down prescription drugs, over-the-counter medicines, supplements, topical products, injections, and products obtained online. Record the name and how you actually use each one, including recent starts or stops. AHRQ advises bringing a full medicine list to a doctor visit. A clinician cannot evaluate an interaction if a research-use product or supplement is omitted because it feels separate from “real medicine.” AHRQ: Talk with your doctor

For an approved peptide medicine, the label may name interactions or warn about use with other treatments. A clinician should check diagnoses, allergies, and prior reactions as well as the list. For example, diabetes medicines can affect low-blood-glucose risk; the exact significance depends on the product and patient. MedlinePlus explains hypoglycemia and the role of medicines that lower blood glucose. Do not adjust any medicine from a general article. FDA: Labeling FAQ for prescription medicines MedlinePlus: Hypoglycemia

If a telehealth service, primary clinician, specialist, and pharmacy each hold different records, a new prescription may not appear in everyone’s chart. Bring an updated list to each visit and tell the prescriber when another clinician changes a drug. AHRQ PSNet notes that multiple medicines and clinicians can increase interaction and side-effect risk, especially in older adults. The list helps every clinician interpret new symptoms. AHRQ PSNet: Medication errors and adverse drug events

Ask why each new medicine is being added, what could interact, and whether an existing drug should change. Get any changes in writing. AHRQ’s medicine guide also emphasizes keeping track of medicines and asking questions. A reconciled list is a working document, not a one-time form submitted at checkout. AHRQ: Questions before taking medicine

For each item, record its full name, strength, why you take it, prescriber, and the date it was started or changed. Include medicines used only occasionally, such as rescue products, and note any product you stopped because of an adverse effect. Bring the actual packages when names are uncertain. The purpose is to give the clinician enough detail to check for overlap and explain a new symptom. AHRQ: Talk with your doctor

A patient may hesitate to mention something bought for research use, but a clinician needs an accurate exposure history. The label may not reliably establish the contents, which should be stated as uncertainty rather than hidden. Tell the clinician what the package said, where it came from, when it was used, and what symptoms followed. That information can affect testing and care even if the product was not a lawful patient medicine. FDA: Considering an online pharmacy